Delving into the Latest Updates on Serrapeptase with Synapse

Overview

Basic Info

Drug Type

Enzyme

Synonyms

Serrapeptase (JAN), Serratiopeptidase, Danzen

+ [3]

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [1]

Active Indication

AsthmaBronchitisSinusitis

Inactive Indication-

Originator Organization

Takeda Pharmaceutical Co., Ltd.

Active Organization

Tianjin Takeda Pharmaceutical Co. Ltd.

Inactive Organization

Takeda Pharmaceutical Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

JP (01 Jan 1968),

AsthmaBronchitisSinusitis

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 140490643

Source: *****

BACKGROUNDSerratiopeptidase, a serine protease traditionally used as an oral anti-inflammatory drug has been found to show antibiofilm action. Structurally, it comprises of two distinct domains; viz-the N-terminal catalytic domain (Ncat) and a C-terminal RTX (Repeat-In-Toxin) domain (Crtx). Understanding the antibiofilm action of the serratiopeptidase molecule, as well as the antibiofilm action of each of its two domains, was the objective of this study.RESULTSSeparate clones to express the complete recombinant serratiopeptidase protein and its variant containing a mutation in the catalytic site, the N-terminal catalytic domain and its mutant, and the C-terminal Repeat-In-Toxin domain were prepared, and the proteins were purified. The impact of these proteins on pre-existing biofilms, as well as their effect upon addition of these proteins during biofilm formation was investigated.CONCLUSIONSIn our investigation, we have been able to analyze the antibiofilm action of serratiopeptidase in detail. Obtained results conclude that while N-terminally located proteolytic domain of serratiopeptidase conventionally acts against biofilms by hydrolytic activity, the C-terminal domain regulates or prevents biofilm formation by yet unknown mechanism in addition to its known function as an C-terminal located calcium modulated internal chaperone ensuring the proper folding and secretion of the molecule. The study's findings give new evidence that the Crtx domain plays a significant role in antibiofilm action. The proteolytic Ncat domain breaks down pre-formed biofilms. The C-terminal domain, on the other hand, acts as an inhibitor of biofilm formation by regulating or preventing biofilm development.

01 Nov 2024·Annales Pharmaceutiques Françaises

Advances and challenges in serratiopeptidase topical formulation

Review

Author: Patil, Sachin D ; Wagdarikar, Manasi J

Enzymes are a key part of most metabolic processes and are required for the correct functioning of the human body, either directly or indirectly. Proteolytic enzymes aid in the digestion of proteins in the body. Proteolytic enzymes are created in the pancreas naturally, but they can also be found in certain diets. Serratiopeptidase is an enzyme found in the stomach wall of silkworms and produced from S. marcescens strain. Less solubility, toxicity, instability, incompatibility, and less penetration are all common issues with Serratiopeptidase drug delivery. Because of its proteinaceous nature, serratiopeptidase is susceptible to enzymatic breakdown in the gastrointestinal system. It also has a low permeability through the intestinal barrier due to its hydrophilic nature. Depending on the features of the medicine, a suitable delivery mechanism is required. Topical formulation may eliminate the risk of gastric degradation of drug and increase direct permeation through skin and show effects. Topical SRP may effectively lower inflammatory markers, as it has been found to have superior anti-inflammatory effects than topical NSAIDs. Serratiopeptidase topical formulations could be more effective than nonsteroidal anti-inflammatory medications in treating local inflammation. This article reviews studies on various topical formulations.

01 Sep 2024·Journal of Clinical Orthopaedics and Trauma

Efficacy and safety of serrapeptase on ankle sprain cases: A single center prospective comparative study

Article

Author: Stamati, Athina ; Lyrtzis, Christos ; Anastasopoulos, Nikolaos ; Paraskevas, Georgios

BackgroundNon-steroid anti-inflammatory drugs (NSAIDs) rank among the frequently prescribed medications for addressing pain and inflammation. Although they are powerful pain relievers, their side effects are indisputable. Serrapeptase, a serine protease, exhibits anti-inflammatory and anti-oedemic activity without the side effects of NSAIDs. We aim to assess the efficacy and safety of serrapeptase in the treatment of pain and edema in ankle sprains.MethodsIn a single-centre prospective comparative study, 76 patients aged 18-53 with Grade II ankle sprains were assigned to either a serrapeptase intervention group (n = 38) receiving 5 mg serrapeptase (two tablets, three times per day) for ten days, or a control group (n = 38) receiving 500 mg paracetamol (three times per day) for the same duration. Ankle joint edema was assessed using both Figure-of-Eight and water-displacement methods. Pain was assessed with Visual Analogue Scale (V.A.S.). Within-groups and between-groups analyses were performed in the 3rd and 10th day.ResultsBoth groups exhibited reduced edema and pain over time. Serrapeptase demonstrated a superior reduction in ankle joint edema on the third and tenth day compared to paracetamol, while pain management did not differ significantly.ConclusionSerrapeptase exhibited better efficacy than paracetamol in reducing ankle joint edema, highlighting its potential as an alternative treatment.Level of evidenceLevel II, prospective comparative trial without randomization.

100 Deals associated with Serrapeptase

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03356	-	B06AA	DB13131

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Asthma	CN	Tianjin Takeda Pharmaceutical Co. Ltd.	01 Jan 2000
Bronchitis	CN	Tianjin Takeda Pharmaceutical Co. Ltd.	01 Jan 2000
Sinusitis	CN	Tianjin Takeda Pharmaceutical Co. Ltd.	01 Jan 2000

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02493179 (Pubmed \| BMC Oral Health)	Phase 4	-	133	Serratiopeptidase	(akbcptzygy) = odgcrbxvey kdgvgnpqqj (uhanotqosd ) View more	-	02 Mar 2021
				Placebo	(akbcptzygy) = borhcepsax kdgvgnpqqj (uhanotqosd ) View more